Corvus Pharmaceuticals (CRVS) Competitors $4.19 -0.22 (-4.99%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$4.24 +0.05 (+1.17%) As of 02/21/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRVS vs. ANIP, DAWN, ADPT, RCUS, CALT, SYRE, SPRY, OCUL, XNCR, and ETNBShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include ANI Pharmaceuticals (ANIP), Day One Biopharmaceuticals (DAWN), Adaptive Biotechnologies (ADPT), Arcus Biosciences (RCUS), Calliditas Therapeutics AB (publ) (CALT), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Ocular Therapeutix (OCUL), Xencor (XNCR), and 89bio (ETNB). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. ANI Pharmaceuticals Day One Biopharmaceuticals Adaptive Biotechnologies Arcus Biosciences Calliditas Therapeutics AB (publ) Spyre Therapeutics ARS Pharmaceuticals Ocular Therapeutix Xencor 89bio ANI Pharmaceuticals (NASDAQ:ANIP) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation. Which has better valuation and earnings, ANIP or CRVS? ANI Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioANI Pharmaceuticals$486.82M2.50$18.78M-$0.55-105.35Corvus PharmaceuticalsN/AN/A-$27.03M-$0.93-4.51 Does the media prefer ANIP or CRVS? In the previous week, ANI Pharmaceuticals had 11 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 12 mentions for ANI Pharmaceuticals and 1 mentions for Corvus Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.49 beat Corvus Pharmaceuticals' score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ANIP or CRVS? ANI Pharmaceuticals presently has a consensus price target of $77.71, suggesting a potential upside of 34.13%. Corvus Pharmaceuticals has a consensus price target of $12.38, suggesting a potential upside of 195.35%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Is ANIP or CRVS more profitable? Corvus Pharmaceuticals has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ANI Pharmaceuticals-1.28% 15.87% 6.88% Corvus Pharmaceuticals N/A -70.71%-45.90% Does the MarketBeat Community favor ANIP or CRVS? ANI Pharmaceuticals received 143 more outperform votes than Corvus Pharmaceuticals when rated by MarketBeat users. Likewise, 64.39% of users gave ANI Pharmaceuticals an outperform vote while only 61.91% of users gave Corvus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformANI PharmaceuticalsOutperform Votes43464.39% Underperform Votes24035.61% Corvus PharmaceuticalsOutperform Votes29161.91% Underperform Votes17938.09% Which has more risk & volatility, ANIP or CRVS? ANI Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Do institutionals and insiders believe in ANIP or CRVS? 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryANI Pharmaceuticals beats Corvus Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$269.25M$7.04B$5.77B$8.95BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-4.516.1326.4618.81Price / SalesN/A314.26449.1576.64Price / CashN/A67.8344.0437.47Price / Book5.306.747.634.64Net Income-$27.03M$138.11M$3.18B$245.69M7 Day Performance-14.14%-2.02%-1.82%-2.63%1 Month Performance-19.73%-1.54%0.22%-2.37%1 Year Performance82.17%-3.14%17.49%13.65% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals1.9049 of 5 stars$4.19-5.0%$12.38+195.3%+82.2%$269.25MN/A-4.5130News CoverageHigh Trading VolumeANIPANI Pharmaceuticals4.3765 of 5 stars$58.92-0.5%$77.71+31.9%+0.5%$1.24B$486.82M-107.13600DAWNDay One Biopharmaceuticals2.1092 of 5 stars$12.26+0.4%$35.71+191.3%-15.7%$1.24B$101.95M-11.9060Upcoming EarningsInsider TradeNews CoverageADPTAdaptive Biotechnologies3.6449 of 5 stars$8.33-2.2%$8.30-0.4%+116.5%$1.23B$170.28M-6.22790Analyst ForecastInsider TradeRCUSArcus Biosciences2.7595 of 5 stars$13.05+2.8%$32.67+150.3%-32.7%$1.19B$117M-4.14500Analyst ForecastAnalyst RevisionNews CoverageGap UpCALTCalliditas Therapeutics AB (publ)0.1154 of 5 stars$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180SYRESpyre Therapeutics2.0845 of 5 stars$22.92+1.1%$54.83+139.2%+4.0%$1.18B$890,000.00-3.07100Analyst UpgradeNews CoverageSPRYARS Pharmaceuticals3.199 of 5 stars$12.02+0.8%$28.80+139.6%+50.7%$1.17B$30,000.00-23.5790Analyst ForecastNews CoverageGap UpOCULOcular Therapeutix3.4059 of 5 stars$7.28-2.7%$17.00+133.5%-6.9%$1.14B$58.44M-5.52230XNCRXencor3.4795 of 5 stars$16.31+0.1%$34.88+113.8%-34.7%$1.14B$168.34M-5.10280ETNB89bio3.1186 of 5 stars$10.57-1.4%$31.43+197.3%+5.9%$1.12BN/A-3.6340Analyst Forecast Related Companies and Tools Related Companies ANI Pharmaceuticals Alternatives Day One Biopharmaceuticals Alternatives Adaptive Biotechnologies Alternatives Arcus Biosciences Alternatives Calliditas Therapeutics AB (publ) Alternatives Spyre Therapeutics Alternatives ARS Pharmaceuticals Alternatives Ocular Therapeutix Alternatives Xencor Alternatives 89bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRVS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRVS Stock Alerts